An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study-Reference-Cited by-同舟云学术

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study

Published:2018-04-20 Issue:4 Volume:18 Page:435-446
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Lazzaro Carlo¹^ORCID,Barone Carlo²,Caprioni Francesco³,Cascinu Stefano⁴,Falcone Alfredo⁵,Maiello Evaristo⁶,Milella Michele⁷,Pinto Carmine⁸,Reni Michele⁹,Tortora Giampaolo¹⁰

Affiliation:

1. Studio di Economia Sanitaria, Milan, Italy

2. Policlinico Gemelli, Rome, Italy

3. Ospedale S. Martino, Genoa, Italy

4. Policlinico di Modena, Modena, Italy

5. Azienda Ospedaliera Universitaria Pisana, Pisa, Italy

6. Casa Sollievo della Sofferenza, S. Giovanni Rotondo, Italy

7. Istituto Nazionale Tumori Regina Elena, Rome, Italy

8. Ospedale S. Maria Nuova, Reggio Emilia, Italy

9. Ospedale S. Raffaele, Milan, Italy

10. Azienda Ospedaliera Universitaria Integrata Borgo Roma, Verona, Italy

Funder

Health Economics and Outcomes Research Unit of Celgene s.r.l

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2018.1464394

Reference75 articles.

1. Associazione Italiana di Oncologia Medica (AIOM) [Internet]. Milan (Italy): AIOM. I numeri del cancro in Italia; 2015. [cited 2017 Dec 22]. Available from: http://www.registri-tumori.it/PDF/AIOM2015/I_numeri_del_cancro_2015.pdf Italian.

2. Ervik M, Lam F, Ferlay Jet A [Internet]. Cancer Today. Lyon (France): International Agency for Research on Cancer; [cited 2017 Dec 22]. Available from: http://gco.iarc.fr/today

3. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

4. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

5. Hypersensitivity reactions from taxol.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Framework for developing cost-effectiveness analysis threshold: the case of Egypt;Journal of the Egyptian Public Health Association;2024-06-03

2. On cost-effectiveness analysis, quality-adjusted life years, and cost-effectiveness threshold values of gemcitabine plus nab-paclitaxel versus gemcitabine alone in metastatic pancreatic cancer in the French setting;Therapeutic Advances in Medical Oncology;2024-01

3. French multi-institutional cost-effectiveness analysis of gemcitabine plus nab-paclitaxel versus gemcitabine alone as second-line treatment in metastatic pancreatic cancer patients;Therapeutic Advances in Medical Oncology;2024-01

4. Economic Burden of Pancreatic Cancer in Europe: a Literature Review;Journal of Gastrointestinal Cancer;2022-04-26

5. Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing–remitting multiple sclerosis in Italy;Neurological Sciences;2022-04-14